Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capivasertib + Enzalutamide in mCRPC
NCT02525068Phase 2Unknown
- Sponsor
- The Institute of Cancer Research
- Start
- Dec 2014
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capivasertib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by The Institute of Cancer Research. Status: unknown.
02
Drugs
capivasertib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02525068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02525068.